- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Emma Guttman-Yassky: Strong Real-World Results of Biologics, JAK Inhibitors in AD
Some of the results with biologics and Janus kinase (JAK) inhibitors for atopic dermatitis have been better in practice compared with clinical trials, said Emma Guttman-Yassky, MD, PhD, FAAD, of the Icahn School of Medicine at Mount Sinai.
It’s not uncommon for real-world results and outcomes for a treatment to be worse than those seen in clinical trials, which are more tightly controlled and have strict inclusion criteria. However, some of the results with biologics and Janus kinase (JAK) inhibitors for atopic dermatitis have been better in practice, said Emma Guttman-Yassky, MD, PhD, FAAD, the Waldman Professor and System Chair of Dermatology and Immunology at the Icahn School of Medicine at Mount Sinai, the director of the Center for Excellence in Eczema and the Occupational Dermatitis Clinic, and director of the Laboratory for Inflammatory Skin Diseases.
The first biologic to treat atopic dermatitis was approved in 2017 and the first oral JAK inhibitors were approved in January 2022.
Transcript
With a couple of years of data of real-world use for biologics and JAK inhibitors to treat atopic dermatitis, what have you seen regarding real-world adherence and efficacy compared with what was seen in the clinical trials?
So yes, for some, actually, we see better results in practice. One such drug is tralokinumab, which targets IL-13. I have to say, I have a very good experience in real life. Part of it is that in the clinical trial, they had a very long washout from topical steroids, and that may have resulted in less good data. But we have good experience now in the real life and also less conjunctivitis, so I think that is good.
Also, I have very good experience now with the JAK inhibitors, both upadacitinib, and also very good experience with abrocitinib from Pfizer—maybe a little bit better than what we've seen in clinical studies. We need to remember their clinical study was 12 weeks, whereas upadacitinib was 16 weeks, and that may make some difference. But we see very good results in real life.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Valoctocogene Roxaparvovec Dramatically Reduces Bleeding in Hemophilia A
May 15th 2024New study findings demonstrate that valoctocogene roxaparvovec, a gene therapy for severe hemophilia A, significantly reduces bleeding episodes and dependency on factor VIII infusions over a 3-year period, while maintaining a favorable safety profile.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
